Vir Biotechnology

VIRNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$1.492 B

$8.82 +0.63%

Close of 7 Aug 2026

Revenue

$68.6M

#2641 by revenue

Earnings

-$438.0M

Loss-making

Shares outstanding

169,215,958

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#39Maze TherapeuticsMAZE$1.59B
#40SL ScienceSLBT$1.50B
#41Vir BiotechnologyVIR$1.49B
#42Monte Rosa TherapeuticsGLUE$1.34B
#43NovavaxNVAX$1.31B

Where these numbers come from

Share counts and financials for Vir Biotechnology are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.